Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.

Crooks ET, Grimley SL, Cully M, Osawa K, Dekkers G, Saunders K, Rämisch S, Menis S, Schief WR, Doria-Rose N, Haynes B, Murrell B, Cale EM, Pegu A, Mascola JR, Vidarsson G, Binley JM.

PLoS Pathog. 2018 May 2;14(5):e1007024. doi: 10.1371/journal.ppat.1007024. eCollection 2018 May.

2.

Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, Tong T, Li J, Nagarajan R, Ozorowski G, Ambrozak DR, Asokan M, Bailer RT, Bennici AK, Chen X, Doria-Rose NA, Druz A, Feng Y, Joyce MG, Louder MK, O'Dell S, Oliver C, Pancera M, Connors M, Hope TJ, Kepler TB, Wyatt RT, Ward AB, Georgiev IS, Kwong PD, Mascola JR, Binley JM.

Immunity. 2017 May 16;46(5):777-791.e10. doi: 10.1016/j.immuni.2017.04.011.

3.

Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Crooks ET, Osawa K, Tong T, Grimley SL, Dai YD, Whalen RG, Kulp DW, Menis S, Schief WR, Binley JM.

Virology. 2017 May;505:193-209. doi: 10.1016/j.virol.2017.02.024. Epub 2017 Mar 6.

4.

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.

Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-Pazner S, Baxa U, Schön A, Freire E, Shapiro L, Lee KK, Arthos J, Munro JB, Blanchard SC, Mothes W, Binley JM, McDermott AB, Mascola JR, Kwong PD.

Nat Struct Mol Biol. 2015 Jul;22(7):522-31. doi: 10.1038/nsmb.3051. Epub 2015 Jun 22.

5.

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.

Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, Huang X, Kulp D, Osawa K, Muranaka J, Stewart-Jones G, Destefano J, O'Dell S, LaBranche C, Robinson JE, Montefiori DC, McKee K, Du SX, Doria-Rose N, Kwong PD, Mascola JR, Zhu P, Schief WR, Wyatt RT, Whalen RG, Binley JM.

PLoS Pathog. 2015 May 29;11(5):e1004932. doi: 10.1371/journal.ppat.1004932. eCollection 2015 May.

6.

Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques.

Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, Apetrei C, Binley JM.

Virology. 2014 May;456-457:55-69. doi: 10.1016/j.virol.2014.03.015. Epub 2014 Mar 29.

7.

Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, Apetrei C, Binley JM.

Virology. 2014 May;456-457:55-69.

8.

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR.

Nature. 2014 May 1;509(7498):55-62. doi: 10.1038/nature13036. Epub 2014 Mar 2.

9.

Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.

Tong T, Osawa K, Robinson JE, Crooks ET, Binley JM.

J Virol. 2013 Aug;87(16):9233-49. doi: 10.1128/JVI.01145-13. Epub 2013 Jun 5.

10.

M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.

Selhorst P, Grupping K, Tong T, Crooks ET, Martin L, Vanham G, Binley JM, Ariën KK.

Retrovirology. 2013 Feb 1;10:12. doi: 10.1186/1742-4690-10-12.

11.

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Tong T, Crooks ET, Osawa K, Binley JM.

J Virol. 2012 Apr;86(7):3574-87. doi: 10.1128/JVI.06938-11. Epub 2012 Feb 1.

12.

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.

J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.

13.

Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Crooks ET, Tong T, Osawa K, Binley JM.

J Virol. 2011 Jun;85(12):5825-39. doi: 10.1128/JVI.00154-11. Epub 2011 Apr 6.

14.

Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW.

J Virol. 2010 Jun;84(11):5637-55. doi: 10.1128/JVI.00105-10. Epub 2010 Mar 24.

15.

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, Durso RJ, Parsons TF, Maddon PJ, Moore JP, Olson WC.

Vaccine. 2009 Aug 13;27(37):5120-32. doi: 10.1016/j.vaccine.2009.06.037. Epub 2009 Jun 28.

16.

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.

17.

Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, Hoxie JA, Robinson JE, Moore PL, Binley JM.

Virology. 2008 Aug 1;377(2):364-78. doi: 10.1016/j.virol.2008.04.045. Epub 2008 Jun 9.

18.

Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination.

Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S.

J Virol. 2008 Aug;82(15):7369-78. doi: 10.1128/JVI.00562-08. Epub 2008 May 21.

19.

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, de Vries RP, Wiley C, Zharkikh I, Schülke N, Roux KH, Montefiori DC, Burton DR, Binley JM.

Virology. 2007 Sep 30;366(2):245-62. Epub 2007 Jun 19.

20.

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.

J Virol. 2007 Apr;81(8):4033-43. Epub 2007 Feb 7.

21.
22.

Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, Franti M, Schülke N, Binley JM.

Hum Antibodies. 2005;14(3-4):101-13.

23.

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM.

J Virol. 2006 Mar;80(5):2515-28.

Supplemental Content

Loading ...
Support Center